Pharma Business - January 7, 2020
AstraZeneca’s triple-combination therapy approved in China for patients with COPD
Budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This is the first approval by the National Medical Products Administration for a triple-combination therapy in a pressurised metered-dose inhaler (pMDI), which uses the innovative Aerosphere delivery technology. The approval follows a priority review and is based on results from […]
Acquisition - December 20, 2019
AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries
AstraZeneca has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries1 to Juvisé Pharmaceuticals. The medicines, used primarily to treat breast and prostate cancers, have lost their compound patent protection in these countries. AstraZeneca already divested the rights to both Arimidexand Casodex in the US in […]
Clinical Trials - December 12, 2019
Promising data from AstraZeneca and Daiichi Sankyo’s Trastuzumab deruxtecan trial
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in the Phase II HER2-positive metastatic breast cancer trial. AstraZeneca and Daiichi Sankyo have presented positive detailed data from the global Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast […]
Agreement - December 3, 2019
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada. “This divestment […]
Pharma Business - November 18, 2019
AstraZeneca’s Qtrilmet approved in the EU for treatment of type-2 diabetes
The European Commission (EC) has approved Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets to improve glycaemic control in adults with type-2 diabetes (T2D). The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with inadequately controlled T2D. The primary endpoint in […]
Global report - November 6, 2019
AstraZeneca announces large-scale initiatives in China to advance global medicine R&D
AstraZeneca has announced three large-scale initiatives to build on the company’s commitment to China and advance global research and development for innovative new medicines. The announcements, made at the 2nd annual China International Import Expo (CIIE) in Shanghai, include the creation of a new Global R&D Centre and an artificial intelligence (AI) Innovation Centre, both […]
